TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31578887

Group type: EXPERIMENTAL
Intervention: phacoemulsification + visco-goniosynechialysis + goniotomy
Number of subjects: 61

Group type: COMPARATOR
Intervention: phacoemulsification + visco-goniosynechialysis
Number of subjects: 61
Study: 30612511

Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy with internet-based videos for 60 minutes once a week for 3 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group received unstructured interviews for 25 to 30 minutes during the same period
Number of subjects: 32
Study: 30235002

Group type: EXPERIMENTAL
Intervention: Fearon criteria (weight loss >5% OR weight loss >2% with either BMI <20 kg/m2 or sarcopenia)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Clinical assessment by oncologist
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Clinically cachectic patients
Number of subjects: 69
Study: 27075910

Group type: EXPERIMENTAL
Intervention: E‐HFP with BCC strategy implemented by older women leaders
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1767
Study: 25243781

Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ (olmesartan/amlodipine/hydrochlorothiazide)
Number of subjects: 2690

Group type: COMPARATOR
Intervention: OLM/AML (olmesartan/amlodipine)
Number of subjects: 2690
Study: 22771125

Group type: EXPERIMENTAL
Intervention: Patient-controlled cognitive-behavioral (CB) intervention using relaxation, imagery, or distraction exercises delivered via an MP3 player for two weeks.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Waitlist control condition for the same two week period.
Number of subjects: 86
Study: 20615267

Group type: EXPERIMENTAL
Intervention: 60 mg Fe (ferrous sulphate) daily
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Fe plus 400 μg folic acid daily
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Fe plus 2 mg retinol and 1 mg riboflavin daily
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 164
Study: 17284502

Group type: EXPERIMENTAL
Intervention: Computer-based tutorial on inhaler technique
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no tutorial)
Number of subjects: 34
Study: 16099888

Group type: EXPERIMENTAL
Intervention: Bed rest combined with normoenergetic nutrition
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypoenergetic diet under ambulatory conditions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bed rest combined with hypoenergetic diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control conditions (ambulatory)
Number of subjects: 10
Study: 12803689

Group type: EXPERIMENTAL
Intervention: Increased salt intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avoidance of triggering factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravascular volume expansion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive head-up tilt testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical history
Number of subjects: 0
Study: 10469179

Group type: EXPERIMENTAL
Intervention: Recombinant FVIIa (rFVIIa) treatment
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Recombinant FVIIa (rFVIIa) treatment during surgery
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Adverse events during treatment episodes
Number of subjects: 67
Study: 7502551

Group type: EXPERIMENTAL
Intervention: Triple therapy (bismuth subsalicylate, metronidazole, tetracycline plus ranitidine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dual therapy (omeprazole and amoxicillin)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cured H. pylori infection (both therapies)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Persistently infected with H. pylori
Number of subjects: 40
Study: 2138684

Group type: EXPERIMENTAL
Intervention: Diclofenac + vitamins B1 (50 mg), B6 (50 mg), B12 (0.25 mg)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Diclofenac (25 mg)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Diclofenac + vitamins B1, B6, B12
Number of subjects: 418
Study: 6103208

Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30807613

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 28105519

Group type: EXPERIMENTAL
Intervention: HbA1c of 8.0% (64 mmol/mol)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: HbA1c of 6.0% (42 mmol/mol)
Number of subjects: 117
Study: 26683246

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 342

Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 342
Study: 25157406

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 1480
Study: 22466021

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment plus usual neck exercises (PTcb group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual neck exercises alone (PT group)
Number of subjects: 80
Study: 18688657

Group type: COMPARATOR
Intervention: TAS (tacrolimus, azathioprine, corticosteroids)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: TAS + B (tacrolimus, azathioprine, corticosteroids, and basiliximab)
Number of subjects: 192
Study: 17141491

Group type: EXPERIMENTAL
Intervention: Mao-to (0.06 g/kg body wt./dose three times daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mao-to plus Oseltamivir
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oseltamivir (2 mg/kg body wt./dose twice daily)
Number of subjects: 60
Study: 15849804

Group type: EXPERIMENTAL
Intervention: 2D plus 4D ultrasound (Group 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2D ultrasound only (Group 1)
Number of subjects: 100
Study: 11830606

Group type: EXPERIMENTAL
Intervention: Screened group (mammography, fecal occult blood detection, chest x-ray)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 10069678

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion with free NO availability
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion with NO clamp (using L-NMMA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion with vitamin C co-infusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline control during angiotensin II infusion
Number of subjects: 26
Study: 7628024

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg, approximately 1.4 mg.kg‐1 mean) administered at 9:00 pm the night before surgery and at 5:30 am on the morning of surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo followed by Lansoprazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lansoprazole followed by Placebo
Number of subjects: 100
Study: 2035037

Group type: EXPERIMENTAL
Intervention: Pneumatic leg brace (Aircast)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cast immobilization
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 6119925

Group type: EXPERIMENTAL
Intervention: Nadolol 0.3%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nadolol 1.5%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nadolol 2%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 31784433

Group type: EXPERIMENTAL
Intervention: Combination of Traditional Chinese Medicine (TCM) and Western medicine (Xin Jia Xuan Bai Cheng Qi Decoction)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Conventional therapy alone (Western standard Medicine)
Number of subjects: 360
Study: 28967272

Group type: EXPERIMENTAL
Intervention: Initial triple disease-modifying anti-rheumatic drug therapy
Number of subjects: 265

Group type: COMPARATOR
Intervention: Methotrexate monotherapy with glucocorticoid bridging
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 265
Study: 26796681

Group type: EXPERIMENTAL
Intervention: Galantamine (AD G)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (AD P+G)
Number of subjects: 28
Study: 24934915

Group type: EXPERIMENTAL
Intervention: Noncultured autologous cell grafting using a six-well plate technique
Number of subjects: 8
Study: 21626051

Group type: EXPERIMENTAL
Intervention: Capecitabine 750 mg/m² BID for 14 days of a 21-day cycle
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Capecitabine 1,000 mg/m² BID for 14 days of a 21-day cycle
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Capecitabine 1,000 mg BID flat dose with continuous dosing of sorafenib 400 mg BID
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study: 19602610

Group type: EXPERIMENTAL
Intervention: Twice-daily icodextrin administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-daily icodextrin administration
Number of subjects: 0
Study: 17898957

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture combined with Paroxetine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Paroxetine alone
Number of subjects: 42
Study: 15736450

Group type: EXPERIMENTAL
Intervention: Extended field (EF) irradiation after four cycles of ABVD regimen
Number of subjects: 210

Group type: COMPARATOR
Intervention: Involved field (IF) irradiation after four cycles of ABVD regimen
Number of subjects: 210
Study: 11790216

Group type: EXPERIMENTAL
Intervention: Oral antidiabetic agents (various classes)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination of oral antidiabetic agents
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sulfonylureas and metformin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 12070396

Group type: EXPERIMENTAL
Intervention: Soap and water (group A)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Clinisan (group B)
Number of subjects: 93
Study: 9645291

Group type: EXPERIMENTAL
Intervention: Desflurane (DES)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Isoflurane (ISO)
Number of subjects: 52
Study: 7935701

Group type: EXPERIMENTAL
Intervention: Amphotericin B (0.5 to 0.6 mg per kilogram of body weight per day)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Fluconazole (400 mg per day)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 206

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 206
Study: 3341322

Group type: EXPERIMENTAL
Intervention: Nonoscillating waterbeds
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional bassinets
Number of subjects: 30
Study: 1554112

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 34

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Flunitrazepam
Number of subjects: 34
Study: 894086

Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated Mycoplasma pneumoniae vaccine
Number of subjects: 7861

Group type: COMPARATOR
Intervention: Phosphate‐buffered saline with formalin (control)
Number of subjects: 7861
Study: 31034314

Group type: EXPERIMENTAL
Intervention: Two Minute Walk Test (2MWT) under dual task conditions overground
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Two Minute Walk Test (2MWT) under dual task conditions on a self-paced treadmill
Number of subjects: 23

Group type: COMPARATOR
Intervention: Comparison of overground and treadmill velocities
Number of subjects: 23
Study: 29615070

Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT)
Number of subjects: 20
Study: 26735927

Group type: EXPERIMENTAL
Intervention: Black‐White cardiovascular‐related disparities + neutral health topics
Number of subjects: 86

Group type: COMPARATOR
Intervention: Neutral health topics only
Number of subjects: 86
Study: 24491296

Group type: EXPERIMENTAL
Intervention: Unilateral ovarian suspension for 36-48 hours
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (unsuspended ovary)
Number of subjects: 55
Study: 22525009

Group type: EXPERIMENTAL
Intervention: Pranayama
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study: 19082851

Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (CRD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-fat diet (LFD)
Number of subjects: 40
Study: 17965494

Group type: EXPERIMENTAL
Intervention: Nocturnal home oxygen therapy (HOT)
Number of subjects: 53
Study: 16306060

Group type: EXPERIMENTAL
Intervention: Half the recommended dose of vitamin A
Number of subjects: 4983

Group type: COMPARATOR
Intervention: Full recommended dose of vitamin A
Number of subjects: 4983
Study: 11907388

Group type: COMPARATOR
Intervention: Paracetamol (P group, n = 8)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Paracetamol and tramadol (PT group, n = 29)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Paracetamol and nalbuphine (PN group, n = 27)
Number of subjects: 64
Study: 10660202

Group type: EXPERIMENTAL
Intervention: CHART (Continuous Hyperfractionated Accelerated Radiotherapy) delivering 54 Gy in 36 fractions on 12 consecutive days
Number of subjects: 918

Group type: COMPARATOR
Intervention: Conventional fractionation delivering 66 Gy in 33 fractions over 6‐7 weeks
Number of subjects: 918
Study: 7654268

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole, 160 mg/800 mg twice daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Nitrofurantoin, 100 mg four times daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Cefadroxil, 500 mg twice daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Amoxicillin, 500 mg three times daily
Number of subjects: 147
Study: 1969252

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.167 microgram/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.33 microgram/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.67 microgram/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microgram/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (all doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (optimal dose range)
Number of subjects: 20
Study: 435650

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study: 31630703

Group type: EXPERIMENTAL
Intervention: Collaborative care approach (COACH) provided by a team including village doctor, aging worker, and psychiatrist for 12 months
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Collaborative care approach (COACH)
Number of subjects: 38
Study: 31664444

Group type: EXPERIMENTAL
Intervention: Combination therapy of 2500 mg of l-citrulline and 250 mg of metformin 3 times a day for 26 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 29102983

Group type: EXPERIMENTAL
Intervention: Facilitated access to an alcohol reduction website (via brochure from GP)
Number of subjects: 763

Group type: COMPARATOR
Intervention: Face-to-face brief intervention (BI)
Number of subjects: 763
Study: 26475629

Group type: EXPERIMENTAL
Intervention: South Asian Heart Lifestyle Intervention (SAHELI) - 6 interactive group classes focused on increasing physical activity, healthful diet, weight, and stress management, plus follow-up telephone support calls.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group received translated print education materials about ASCVD and healthy behaviors.
Number of subjects: 63
Study: 24592670

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy-based text messaging intervention
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo period
Number of subjects: 5
Study: 22320028

Group type: EXPERIMENTAL
Intervention: Intraoperative ketamine administered as a bolus dose of 0.5 mg/kg in 10 mL of normal saline and a continuous intravenous infusion of 4.0 microg/kg/min
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline infusion (equal volume to ketamine)
Number of subjects: 34
Study: 19772450

Group type: EXPERIMENTAL
Intervention: Simplified titration algorithm (6 U per meal starting dose, adjusted in 2-U increments)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Intensive titration algorithm (doses based on fasting blood glucose, gender, height, and weight, adjusted based on previous 3 days' mean SMBG)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Intensive titration
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Simplified titration
Number of subjects: 358
Study: 17313424

Group type: EXPERIMENTAL
Intervention: 1-month reducing course of oral prednisolone (9 men)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo regimen (12 men)
Number of subjects: 21
Study: 15198881

Group type: EXPERIMENTAL
Intervention: Broncho‐Vaxom (7 mg, oral capsules, one capsule daily for the first 10 days of each month for 3 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (oral capsules, one capsule daily for the first 10 days of each month for 3 months)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Broncho‐Vaxom
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 12572378

Group type: EXPERIMENTAL
Intervention: Jianpi Wenshen Decoction (JWD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loperamide (LPA)
Number of subjects: 0
Study: 9877488

Group type: EXPERIMENTAL
Intervention: Budesonide 1.0 mg by inhalation from a pMDI with a Nebuhaler (with charcoal)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Budesonide 1.0 mg by inhalation from a pMDI with a Nebuhaler (without charcoal)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Budesonide 0.5 mg given intravenously
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Erroneous administration (canister shaken only before the first actuation)
Number of subjects: 15
Study: 7891985

Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine, topically twice daily for 1 week
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 21
Study: 2617284

Group type: EXPERIMENTAL
Intervention: Arginine aspartate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study: 67895

Group type: EXPERIMENTAL
Intervention: COMB I (cyclophosphamide, vincristine, methyl‐CCNU, and bleomycin)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: COMB II (cyclophosphamide, vincristine, methyl‐CCNU, and bleomycin)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Vincristine, methyl‐CCNU, and bleomycin
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Small cell carcinoma group
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Other histologic types
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 106
Study: 29966992

Group type: EXPERIMENTAL
Intervention: ACT + ERP
Number of subjects: 58

Group type: COMPARATOR
Intervention: ERP
Number of subjects: 58
Study: 27337542

Group type: EXPERIMENTAL
Intervention: Representative visual exemplification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual exemplars
Number of subjects: 0
Study: 25104223

Group type: EXPERIMENTAL
Intervention: Collaborative computer game intervention
Number of subjects: 32
Study: 22798522

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 1376
Study: 20876408

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study: 17531897

Group type: EXPERIMENTAL
Intervention: Prophylactic measures such as prostaglandins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification of high-risk patients and vigilant management of the third stage of labor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uterotonic medications
Number of subjects: 0
Study: 16301850

Group type: EXPERIMENTAL
Intervention: Triple therapy (PAC group): PPI (bid), amoxicillin (1,000 mg, bid), clarithromycin (500 mg, bid)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Quadruple therapy (PBMT group): PPI (bid), bismuth subcitrate (300 mg, qid), metronidazole (500 mg, tid), tetracycline (500 mg, qid)
Number of subjects: 149
Study: 11932285

Group type: EXPERIMENTAL
Intervention: Glucose ingestion (50 g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Placebo ingestion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glucose ingestion (50 g) during mental stress
Number of subjects: 24
Study: 9654311

Group type: EXPERIMENTAL
Intervention: i.v./oral therapy with ciprofloxacin plus metronidazole
Number of subjects: 330

Group type: COMPARATOR
Intervention: i.v. therapy with ciprofloxacin plus metronidazole
Number of subjects: 330
Study: 7628206

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 25 mg plus oestradiol cypionate 5 mg (Cyclofem)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate 50 mg plus oestradiol valerate 5 mg (Mesigyna)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both groups (Cyclofem and Mesigyna)
Number of subjects: 21
Study: 2692825

Group type: EXPERIMENTAL
Intervention: 20 mg of ketanserin sublingually
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 10 mg of ketanserin intravenously
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 20 mg of nifedipine sublingually
Number of subjects: 37
Study: 401691

Group type: EXPERIMENTAL
Intervention: Molsydomine 2 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31845903

Group type: EXPERIMENTAL
Intervention: Electronic Screening and Brief Intervention (eSBI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 0
Study: 28766127

Group type: EXPERIMENTAL
Intervention: Obese women with GDM
Number of subjects: 646

Group type: COMPARATOR
Intervention: Obese women without GDM
Number of subjects: 646
Study: 24101160

Group type: EXPERIMENTAL
Intervention: Exclusively open-ended questions (without skillful reflections)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Exclusively multiple choice questions (with skillful reflections)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Including both question types (with skillful reflections)
Number of subjects: 465
Study: 22624828

Group type: EXPERIMENTAL
Intervention: Danish Adult Reading Test (DART)
Number of subjects: 103